ArticleJournal of cancer research and clinical oncology2026
Lactylation-augmented DCBLD1-mediated PDIA3 stabilization reprograms glycolysis metabolism in oesophageal cancer.
Article in Journal of cancer research and clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveHistone lactylation (Hla) represents a novel epigenetic mark priming cells toward the malignant state. Discoidin, CUB, and LCCL domain-containing type I (DCBLD1) has been reported as a carcinogenic gene so far. This project was focused on the functional role of DCBLD1 in oesophageal cancer through the lactate modification pathway.
methodsBiological information evaluated DCBLD1, protein disulfide isomerase family A member 3 (PDIA3) expression and the relationship between the two in oesophageal cancer. RT-qPCR and Western blotting were used to detect DCBLD1 and PDIA3 expression. Western blotting also quantified DCBLD1-lysine lactylation (kla) levels. DCBLD1 half-life was checked by chlorhexidine (CHX) assay. EDU, wound healing, transwell, flow cytometry and Seahorse assays individually appraised cell proliferation, migration, apoptosis and glycolysis. Co-IP assay identified DCBLD1-PDIA3 interaction. Xenografted tumorigenesis was estimated, prior to histological assessment by H&E staining. Glucose consumption and lactate production were also examined to detect glycolysis.
resultsDCBLD1 was highly expressed in esophageal cancer specimens and cells. DCBLD1 half-life was respectively shortened or prolonged in tumor cells challenged with lactate (LA) or the aerobic glycolysis inhibitor 2-deoxy-d-glucose (2-DG). DCBLD1-Kla levels were up-regulated in oesophageal cancer tissues. Lactate dehydrogenase A (LDHA) interference decreased both DCBLD1 expression and DCBLD1-Kla expression. PDIA3 was highly expressed in oesophageal cancer. DCBLD1 was positively correlated with, and interacted with PDIA3 upon LA stimulation. DCBLD1 knockdown inhibited cell proliferation, migration, glycolysis and induced apoptosis, repressed tumor progress and glycolysis in vivo, which were all partially recovered by PDIA3 overexpression. Further LDHA down-regulation aggravated the impacts of DCBLD1 knockdown and PDIA3 overexpression both in vitro and in vivo.
conclusionIt was established that DCBLD1 lactylation bound to PDIA3, contributing to oesophageal cancer malignancy and glycolysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.